Evolving vaccine choices for the continuously evolving avian influenza viruses

CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources

Volumn 3, Issue , 2008, Pages

  Collisson, Ellen W ^a   Singh, Shailbala ^b   Drechsler, Yvonne ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Attenuated; Avian influenza virus; Inactivated; Recombinant; Vaccines

Indexed keywords

EID: 70449503996     PISSN: None     EISSN: 17498848     Source Type: Journal    
DOI: 10.1079/PAVSNNR20083088     Document Type: Review

References (160)

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiological Reviews 1992;56(1):152-79.
2. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. Fundamental Virology, 4th edn. Lippincott-Raven, Philadelphia, PA; 2001. p. 725-69.
3. Mjaaland S, Rimstad E, Falk K, Dannevig BH. Genomic characterization of the virus causing infectious salmon anemia in Atlantic salmon (Salmo salar L.): an orthomyxo-like virus in a teleost. Journal of Virology 1997;71(10):7681-6.
4. Bui M, Wills EG, Helenius A, Whittaker GR. Role of the influenza virus M1 protein in nuclear export of viral ribonucleoproteins. Journal of Virology 2000;74(4):1781-6.
5. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A. Influenza virus matrix protein is the major driving force in virus budding. Journal of Virology 2000;74(24):11538-47.
6. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998;252(2):324-30.
7. Neumann G, Hughes MT, Kawaoka Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO Journal 2000;19(24):6751-8.
8. Hirst GK. The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science 1941;94(2427):22-3.
9. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, Kwong DL, et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nature Medicine 2007;13:147-9.
10. Matrosovich MN, Gambaryan AS, Teneberg S, Piskarev VE, Yamnikova SS, Lvov DK, et al. Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology 1997;233(1):224-34.
11. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proceedings of the National Academy of Sciences, USA 2004;101(13): 4620-4.
12. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of human airway epithelium by human and avian strains of influenza a virus. Journal of Virology 2006;80(16):8060-8.
13. Huang RT, Wahn K, Klenk HD, Rott R. Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology 1980;104(2):294-302.
14. Maeda T, Ohnishi S. Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes. FEBS Letters 1980;122(2):283-7.
15. Bosch FX, Garten W, Klenk HD, Rott R. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of avian influenza viruses. Virology 1981;113(2):725-35.
16. Garten W, Bosch FX, Linder D, Rott R, Klenk HD. Proteolytic activation of the influenza virus hemagglutinin: the structure of the cleavage site and the enzymes involved in cleavage. Virology 1981;115(2):361-74.
17. Ohuchi M, Orlich M, Ohuchi R, Simpson BE, Garten W, Klenk HD, et al. Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology 1989;168(2):274-80.
18. Perdue ML, Garcia M, Beck J, Brugh M, Swayne DE. An Arg-Lys insertion at the hemagglutinin cleavage site of an H5N2 avian influenza isolate. Virus Genes 1996;12(1):77-84.
19. Perdue ML, Garcia M, Senne D, Fraire M. Virulenceassociated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Research 1997;49(2):173-86.
20. Krug RM, Broni BA, Bouloy M. Are the 50 ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs? Cell 1979;18(2):329-34.
21. Lamb RA, Choppin PW. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981;112(2):729-37.
22. Lamb RA, Lai CJ, Choppin PW. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proceedings of the National Academy of Sciences, USA 1981;78(7):4170-4.
23. McCauley JW, Mahy BW, Inglis SC. Nucleotide sequence of fowl plague virus RNA segment 7. Journal of General Virology 1982;58(Pt 1):211-5.
24. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. Rapid evolution of RNA genomes. Science 1982;215(4540):1577-85.
25. Richman DD, Murphy BR, Belshe RB, Rusten HM, Chanock RM, Blacklow NR, et al. Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults. Journal of Infectious Diseases 1977;136(2):256-62.
26. Desselberger U, Nakajima K, Alfino P, Pedersen FS, Haseltine WA, Hannoun C, et al. Biochemical evidence that 'new' influenza virus strains in nature may arise by recombination (reassortment). Proceedings of the National Academy of Sciences, USA 1978;75(7):3341-5.
27. Hayashida H, Toh H, Kikuno R, Miyata T. Evolution of influenza virus genes. Molecular Biology and Evolution 1985;2(4):289-303.
28. Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, St George K, et al. Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathogens 2008;4(2):e1000012.
29. Boni MF, Zhou Y, Taubenberger JK, Holmes EC. Homologous recombination is very rare or absent in human influenza A virus. Journal of Virology 2008;82(10):4807-11.
30. Escorcia M, Vazquez L, Mendez ST, Rodriguez-Ropon A, Lucio E, Nava GM. Avian influenza: genetic evolution under vaccination pressure. Virology Journal 2008;5:15.
31. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. Journal of Virology 2005;79(5):2814-22.
32. Els MC, Laver WG, Air GM. Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses. Virology 1989;170(1):346-51.
33. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Journal of Virology 2004;78(22):12665-7.
34. Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974;61(2):397-410.
35. Ohuchi M, Asaoka N, Sakai T, Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes and Infection 2006;8(5):1287-93.
36. Webster RG, Campbell CH. An inhibition test for identifying the neuraminidase antigen on influenza viruses. Avian Diseases 1972;16(5):1057-66.
37. Aymard-Henry MCM, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenza virus neuraminidase and neuraminidase-inhibition test procedure. Bulletin of the World Health Organization 1973;48(2):199-202.
38. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351(9101):472-7.
39. Slemons RD, Johnson DC, Osborn JS, Hayes F. Type-A influenza viruses isolated from wild free-flying ducks in California. Avian Diseases 1974;18(1):119-24.
40. Panigraphy B, Senne DA, Pearson JE. Subtypes of avian influenza virus (AIV) isolated from exotic passerine and psittacine birds, 1982-1991. In: Proceedings of the Third International Symposium on Avian Influenza, Madison, WI, United States. Animal Health Association; 1992. pp. 136-43.
41. Allwright DM, Burger WP, Geyer A, Terblanche AW. Isolation of an avian influenza A virus from ostiches (Strutheo camelas). Avian Diseases 1993;22:59-65.
42. Alexander DJ. A review of avian influenza in different bird species. Veterinary Microbiology 2000;74:3-13.
43. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA. Global patterns of influenza a virus in wild birds. Science 2006;312(5772):384-8.
44. Slemons RD, Easterday BC. Virus replication in the digestive tract of ducks exposed by aerosol to type-A influenza. Avian Diseases 1978;22(3):367-77.
45. Brown JD, Stallknecht DE, Beck JR, Suarez DL, Swayne DE. Susceptibility of North American ducks and gulls to H5N1 highly pathogenic avian influenza viruses. Emerging Infectious Diseases 2006;12(11):1663-70.
46. Brugh M. Re-examination of pathogenicity, virulence and lethality. Fourth International Symposium on Avian Influenza. United States Animal Health Association, Athens, GA; 1997. pp. 129-33.
47. Hooper P, Selleck P. Pathology of low and high virulent influenza virus infections. Fourth International Symposium on Avian Influenza. United States Animal Health Association, Athens, GA; 1997. pp. 134-41.
48. Swayne DE, Garcia M, Beck JR, Kinney N, Suarez DL. Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine 2000;18(11-12): 1088-95.
49. Garcia M, Crawford JM, Latimer JW, Rivera-Cruz E, Perdue ML. Heterogeneity in the haemagglutinin gene and emergence of the highly pathogenic phenotype among recent H5N2 avian influenza viruses from Mexico. Journal of General Virology 1996;77(Pt 7):1493-504.
50. Weber S, Harder T, Starick E, Beer M, Werner O, Hoffmann B, et al. Molecular analysis of highly pathogenic avian influenza virus of subtype H5N1 isolated from wild birds and mammals in northern Germany. Journal of General Virology 2007;88(Pt 2):554-8.
51. Kido H, Okumura Y, Yamada H, Le TQ, Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current Pharmaceutical Design 2007;13(4):405-14.
52. Hogenkamp A, Isohadouten N, Reemers SS, Romijn RA, Hemrika W, White MR, et al. Chicken lung lectin is a functional C-type lectin and inhibits haemagglutination by influenza A virus. Veterinary Microbiology 2008;130(1-2): 37-46.
53. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. Journal of Biological Chemistry 2005;280(7):5571-80.
54. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nature Immunology 2004;5(12):1219-26.
55. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annual Review of Immunology 2005;23:275-306.
56. Hatada E, Saito S, Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. Journal of Virology 1999;73(3):2425-33.
57. Bergmann M, Garcia-Sastre A, Carnero E, Pehamberger H, Wolff K, Palese P, et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. Journal of Virology 2000;74(13):6203-6.
58. Krug RM, Yuan W, Noah DL, Latham AG. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 2003;309(2): 181-9.
59. Chen Z, Li Y, Krug RM. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 30-end processing machinery. EMBO Journal 1999;18(8):2273-83.
60. Fernandez-Sesma A. The influenza virus NS1 protein: inhibitor of innate and adaptive immunity. Infectious Disorders - Drug Targets 2007;7(4):336-43.
61. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Medicine 1999;5(10):1157-63.
62. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infectious Diseases 2007;13(3):426-35.
63. Couch RB. Advances in influenza virus vaccine research. Annals of the New York Academy of Sciences 1993;685: 803-12.
64. Holt PG, Stumbles PA, McWilliams AS. Functional studies on dendritic cells in the respiratory tract and related mucosal tissues. Journal of Leukocyte Biology 1999;66(2):272-5.
65. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. Journal of Experimental Medicine 2001;193(1):51-60.
66. McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. Journal of Experimental Medicine 2008;205(7):1635-46.
67. Lawrence CW, Braciale TJ. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. Journal of Immunology 2004;173(2):1209-18.
68. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nature Immunology 2007;8(10):1060-6.
69. Seo SH, Collisson EW. Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus. Journal of Virology 1997;71(7):5173-7.
70. Seo SH, Wang L, Smith R, Collisson EW. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. Journal of Virology 1997;71(10):7889-94.
71. Seo SH, Pei J, Briles WE, Dzielawa J, Collisson EW. Adoptive transfer of infectious bronchitis virus primed alphabeta T cells bearing CD8 antigen protects chicks from acute infection. Virology 2000;269(1):183-9.
72. Collisson EW, Pei J, Dzielawa J, Seo SH. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Developmental and Comparative Immunology 2000;24(2-3):187-200.
73. Pei J, Briles WE, Collisson EW. Memory T cells protect chicks from acute infectious bronchitis virus infection. Virology 2003;306(2):376-84.
74. Seo SH, Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. Journal of Virology 2001;75(6):2516-25.
75. Seo SH, Peiris M, Webster RG. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. Journal of Virology 2002;76(10):4886-90.
76. Butterfield WK, Campbell CH. Vaccination of chickens with influenza A/Turkey/Oregon/71 virus and immunity challenge exposure to five strains of fowl plague virus. Proceedings of the Annual Meeting of the United States Animal Health Association 1978;(82):320-4.
77. Crawford JM, Garcia M, Stone H, Swayne D, Slemons R, Perdue ML. Molecular characterization of the hemagglutinin gene and oral immunization with a waterfowl-origin avian influenza virus. Avian Diseases 1998;42(3):486-96.
78. Wan H, Perez DR. Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. Journal of Virology 2007;81(10):5181-91.
79. Lee CW, Senne DA, Suarez DL. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (differentiating infected from vaccinated animals) strategy for the control of avian influenza. Vaccine 2004;22(23-24):3175-81.
80. Luytjes W, Krystal M, Enami M, Pavin JD, Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989;59(6):1107-13.
81. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences, USA 2000;97(11):6108-13.
82. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305(1):192-200.
83. Shi H, Liu XF, Zhang X, Chen S, Sun L, Lu J. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Vaccine 2007;25(42): 7379-84.
84. Li Z, Jiang Y, Jiao P, Wang A, Zhao F, Tian G, et al. The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. Journal of Virology 2006;80(22):11115-23.
85. Wasilenko JL, Lee CW, Sarmento L, Spackman E, Kapczynski DR, Suarez DL, et al. NP, PB1, and PB2 viral genes contribute to altered replication of H5N1 avian influenza viruses in chickens. Journal of Virology 2008;82(9):4544-53.
86. Wood JM, Kawaoka Y, Newberry LA, Bordwell E, Webster RG. Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/Chicken/Pennsylvania/1370/83 infection. Avian Diseases 1985;29(3):867-72.
87. Brugh M, Beard CW, Stone HD. Immunization of chickens and turkeys against avian influenza with monovalent and polyvalent oil emulsion vaccines. American Journal of Veterinary Research 1979;40(2):165-9.
88. Karunakaran D, Newman JA, Halvorson DA, Abraham A. Evaluation of inactivated influenza vaccines in market turkeys. Avian Diseases 1987;31(3):498-503.
89. Lu B, Zhou H, Chan W, Kemble G, Jin H. Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine 2006;24(44-46):6691-3.
90. Lu B, Zhou H, Ye D, Kemble G, Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. Journal of Virology 2005;79(11):6763-71.
91. Donahoe JP. Inactivated avian influenza whole virus vaccines. In: Proceedings of the Fourth International Symposium on Avian Influenza, Athens, GA; 1997.
92. Cardona CJ, Charlton BR, Woolcock PR. Persistence of immunity in commercial egg-laying hens following vaccination with a killed H6N2 avian influenza vaccine. Avian Diseases 2006;50(3):374-9.
93. Scheerlinck JP, Greenwood DL. Particulate delivery systems for animal vaccines. Methods 2006;40(1):118-24.
94. Suarez DL. Overview of avian influenza DIVA test strategies. Biologicals 2005;33(4):221-6.
95. McNulty MS, Allan GM, Adair GM. Efficacy of avian influenza neuraminidase specific vaccines in chickens. Avian Pathology 1986;15:107-15.
96. Tumpey TM, Alvarez R, Swayne DE, Suarez DL. Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus. Journal of Clinical Microbiology 2005;43(2):676-83.
97. Kodihalli S, Sivanandan V, Nagaraja KV, Shaw D, Halvorson DA. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. Vaccine 1994;12(15):1467-72.
98. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006;24(24):5158-68.
99. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 1999;17(18):2265-74.
100. Allen WH, Madelye CR, Kenday AP. Studies with avian influenza A viruses: cross immunity. Journal of General Virology 1971;12:79-84.
101. Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. Virology 1974;22:35-41.
102. Webster RG, Reay PA, Laver WG. Protection against lethal influenza virus with neuraminidase. Virology 1988;164: 230-7.
103. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995;13(15):1399-402.
104. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999;17(18):2237-44.
105. Livingston BD, Higgins D, Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 2006;20(6):335-40.
106. Wysocka M, Bennink Jr. Limiting dilution analysis of memory cytotoxic T lymphocytes specific for individual influenza virus gene products. Cellular Immunology 1988;112(2):425-9.
107. Wolff JA, Maloney RW, Williams P, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt1):1465-8.
108. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: a novel approach to immunization. International Journal of Immunopharmacology 1995;17(2):79-83.
109. Benvenisty N, Reshef L. Direct introduction of genes into rats and expression of the gene. Proceedings of the National Academy of Sciences, USA 1986;83(24):9551-5.
110. Acsadi G, Jiao SS, Jani A, Duke D, Williams P, Chong W, et al. Direct gene transfer and expression into rat heart in vivo. New Biology 1991;3(1):71-81.
111. Deck RR, DeWitt CM, Donnelly JJ, Liu MA, Ulmer JB. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 1997;15(1):71-8.
112. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259(5102):1745-9.
113. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000;18(23):2592-9.
114. Kim SJ, Sung HW, Han JH, Jackwood D, Kwon HM. Protection against very virulent infectious bursal disease virus in chickens immunized with DNA vaccines. Veterinary Microbiology 2004;101(1):39-51.
115. Lee CW, Senne DA, Suarez DL. Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens. Clinical and Vaccine Immunology 2006;13(3):395-402.
116. Roh HJ, Sung HW, Kwon HM. Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-gamma on protective immunity by a DNA vaccine against IBDV in chickens. Journal of Veterinary Science 2006;7(4):361-8.
117. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 1996;5(4):303-10.
118. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunit. Journal of Experimental Medicine 1997;186(10):1623-31.
119. Manders P, Thomas R. Immunology of DNA vaccines: CpG motifs and antigen presentation. Inflammation Research 2000;49(5):199-205.
120. Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. International Archives of Allergy and Immunology 2000;121(2):87-97.
121. Mahmood MS, Siddique M, Hussain I, Khan A, Mansoor MK. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide. Vaccine 2006;24(22):4838-46.
122. Li J, Huang Y, Liang X, Lu M, Li L, Yu L, et al. Plasmid DNA encoding antigens of infectious bursal disease viruses induce protective immune responses in chickens: factors influencing efficacy. Virus Research 2003;98(1):63-74.
123. Lillehoj HS, Ding X, Quiroz MA, Bevensee E, Lillehoj EP. Resistance to intestinal coccidiosis following DNA immunization with the cloned 3-1E Eimeria gene plus IL-2, IL-15, and IFN-gamma. Avian Diseases 2005;49(1):112-7.
124. Hsieh MK, Wu CC, Lin TL. The effect of co-administration of DNA carrying chicken interferon-gamma gene on protection of chickens against infectious bursal disease by DNAmediated vaccination. Vaccine 2006;24(47-48):6955-65.
125. Beard CW, Schnitzlein WM, Tripathy DN. Protection of chickens against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses. Avian Diseases 1991;35(2):356-9.
126. Beard CW, Schnitzlein WM, Tripathy DN. Effect of route of administration on the efficacy of a recombinant fowlpox virus against H5N2 avian influenza. Avian Diseases 1992;36(4):1052-5.
127. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Review of Vaccines 2005;4(1):63-76.
128. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comparative Immunology, Microbiology and Infectious Diseases 2003;26(5-6):343-55.
129. Afonso CL, Tulman ER, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of fowlpox virus. Journal of Virology 2000;74(8):3815-31.
130. Taylor J, Weinberg R, Kawaoka Y, Webster RG, Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 1988;6(6):504-8.
131. Tripathy DN, Schnitzlein WM. Expression of avian influenza virus hemagglutinin by recombinant fowlpox virus. Avian Diseases 1991;35(1):186-91.
132. Swayne DE, Beck JR, Mickle TR. Efficacy of recombinant fowlpox vaccine in protecting chickens against highly pathogenic Mexican-origin H5N2 avian influenza virus. Avian Diseases 1997;41:910-22.
133. Garcia-Garcia J, Humberto RV, Alejandro HM. Experimental studies and field trials with recombinant fowlpox vaccine in broilers in Mexico. In: Proceedings of the Fourth International Symposium on Avian Influenza. Animal Health Association, Athens, GA; 1997.
134. Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, et al. Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences 2006;1081:193-201.
135. Mingxiao M, Ningyi J, Zhenguo W, Ruilin W, Dongliang F, Min Z, et al. Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18. Vaccine 2006;24:4304-11.
136. Bagust TJ, Jones RC, Guy JS. Avian infectious laryngotracheitis. Revue Scientifique et Technique 2000;19(2):483-92.
137. Bagust TJ. Laryngotracheitis (Gallid-1) herpesvirus infection in the chicken. 4. Latency establishment by wild and vaccine strains of ILT virus. Avian Pathology 1986;15:581-95.
138. Han MG, Kim SJ. Efficacy of live virus vaccines against infectious laryngotracheitis assessed by polymerase chain reaction-restriction fragment length polymorphism. Avian Diseases 2003;47(2):261-71.
139. Fahey KJ, York JJ, Bagust TJ. Laryngotracheitis herpesviruses infection in the chicken. II. The adoptive transfer of resistance with immune spleen cells. Avian Pathology 1984;13:265-75.
140. Schnitzlein WM, Winans R, Ellsworth S, Tripathy DN. Generation of thymidine kinase-deficient mutants of infectious laryngotracheitis virus. Virology 1995;209(2): 304-14.
141. Fuchs W, Ziemann K, Teifke JP, Werner O, Mettenleiter TC. The non-essential UL50 gene of avian infectious laryngotracheitis virus encodes a functional dUTPase which is not a virulence factor. Journal of General Virology 2000;81(Pt 3):627-38.
142. Luschow D, Werner O, Mettenleiter TC, Fuchs W. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene. Vaccine 2001;19(30):4249-59.
143. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002;54(8):527-42.
144. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. Journal of Virology 2006;80(4):1959-64.
145. Toro H, Tang DC, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 2007;25(15):2886-91.
146. Toro H, Tang DC, Suarez DL, Zhang J, Shi Z. Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine 2008;26(21):2640-6.
147. Yates VJ, Rhee YO, Fry DE, El Mishad AM, McCormick KJ. The presence of avian adenoviruses and adeno-associated viruses in healthy chickens. Avian Diseases 1976;20(1): 146-52.
148. McFerran JB, Smyth JA. Avian adenoviruses. Revue Scientifique et Technique 2000;19(2):589-601.
149. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proceedings of the National Academy of Sciences, USA 2006;103(21):8203-8.
150. Veits J, Romer-Oberdorfer A, Helferich D, Durban M, Suezer Y, Sutter G, et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008;26(13):1688-96.
151. Youn S, Leibowitz JL, Collisson EW. In vitro assembled, recombinant infectious bronchitis viruses demonstrate that the 5a open reading frame is not essential for replication. Virology 2005;332(1):206-15.
152. Casais R, Davies M, Cavanagh D, Britton P. Gene 5 of the avian coronavirus infectious bronchitis virus is not essential for replication. Journal of Virology 2005;79(13): 8065-78.
153. Cavanagh D, Casais R, Armesto M, Hodgson T, Izadkhasti S, Davies M, et al. Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins. Vaccine 2007;25(30):5558-62.
154. Beato MS, Rigoni M, Milani A, Capua I. Generation of avian influenza reassortant viruses of the H7N5 subtype as potential vaccine candidates to be used in the framework of a 'DIVA' vaccination strategy. Avian Diseases 2007;51(Suppl. 1):479-80.
155. James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM. Use of tetanus toxoid as a differentiating infected from vaccinated animals (DIVA) strategy for sero-surveillance of avian influenza virus vaccination in poultry. Vaccine 2007;25(31):5892-901.
156. Oliveira SC, Harms JS, Afonso RR, Splitter GA. A genetic immunization adjuvant system based on BVP22-antigen fusion. Human Gene Therapy 2001;12(10):1353-9.
157. Mwangi W, Brown WC, Splitter GA, Zhuang Y, Kegerreis K, Palmer GH. Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. Journal of Leukocyte Biology 2005;78(2):401-11.
158. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, et al. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006;354(1):48-57.
159. O'Donnell LA, Clemmer JA, Czymmek K, Schmidt CJ. Marek's disease virus VP22: subcellular localization and characterization of carboxyl terminal deletion mutations. Virology 2002;292(2):235-40.
160. Capua I, Alexander DJ. The challenge of avian influenza to the veterinary community. Avian Pathology 2006;35(3): 189-205.